Chancery Finds Fraud In Cancer Drug Firm's Spinoff Deal
California-based immunotherapy drug developer Harpoon Therapeutics must face damage claims from a Takeda Pharmaceutical subsidiary, after a Delaware vice chancellor's finding that Harpoon effectively misrepresented the scope of a cancer therapy...To view the full article, register now.
Already a subscriber? Click here to view full article